Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change $ Change
grade F $119.26 -0.83% -1.0
ALXN closed down 0.83 percent on Friday, March 24, 2017, on 67 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ALXN trend table...

Date Alert Name Type % Chg
Mar 24 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Mar 23 NR7 Range Contraction -0.83%
Mar 22 Stochastic Buy Signal Bullish -0.68%
Mar 17 Stochastic Buy Signal Bullish -2.31%
Mar 16 Lower Bollinger Band Walk Other -2.57%
Mar 16 Slingshot Bearish Bearish Swing Setup -2.57%
Mar 15 NR7 Range Contraction -2.34%
Mar 15 Lower Bollinger Band Walk Other -2.34%
Mar 13 Stochastic Reached Oversold Other -4.39%
Mar 10 200 DMA Resistance Bearish -6.32%

Older signals for ALXN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 162.0
52 Week Low 109.12
Average Volume 1,937,949
200-Day Moving Average 126.6164
50-Day Moving Average 128.685
20-Day Moving Average 126.041
10-Day Moving Average 121.145
Average True Range 2.9619
ADX 23.03
+DI 15.69
-DI: 30.28
Chandelier Exit (Long, 3 ATRs) 126.9743
Chandelier Exit (Short, 3 ATRs) 125.8457
Upper Bollinger Band 136.948
Lower Bollinger Band 115.134
Percent B (%b) 0.19
Bandwidth 0.173071